Twist Bioscience’s Comprehensive DNA Synthesis Capabilities Expanded as Industry-Leading Enzymatic Synthesis Process Unveiled at Annual J.P. Morgan Healthcare Conference
January 10 2022 - 7:00AM
Business Wire
-- Reveals Plug and Play, Low Cost, No Scar,
Scalable Enzymatic Synthesis 3.0 --
-- Partners with PacBio, Singular Genomics
Enabling New Sequencing Platforms --
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced that it has
developed an innovative, low cost, scarless and scalable enzymatic
DNA synthesis process. With these comprehensive capabilities in
synthesis, Twist offers multiple approaches to serve the growing
number of markets leveraging synthetic DNA. Emily M. Leproust,
Ph.D., CEO and co-founder of Twist Bioscience, will unveil the
advancement during her presentation at the 40th Annual J.P. Morgan
Healthcare Conference.
Twist Enzymatic DNA Synthesis 3.0
Scientists at Twist have worked for the past 18 months to
develop a novel approach to synthesize strands of DNA
enzymatically. By leveraging Twist’s unique gene and variant
library synthesis and screening capabilities, Twist developed novel
enzyme/nucleotide conjugates that drastically reduce the quantity
of nucleotide triphosphate (NTP) used by traditional enzymatic
approaches, which significantly reduces the cost and offers a much
more sustainable method of synthesis. In addition, the linkage
between the enzyme and the nucleotide developed by Twist maintains
the integrity of the DNA, with no ‘scars’ on the nucleobase from
linker molecules. This allows the resulting enzymatically created
synthetic DNA strand to be used interchangeably with naturally
occurring DNA.
“Our culture of innovation and execution has once again
delivered a breakthrough in DNA synthesis, this time using enzymes.
Overcoming a significant drawback of existing enzymatic approaches,
we have been able to create low cost synthetic DNA using enzymes
which also circumvent the issue of scarring, so that the DNA
synthesized using our process is identical to natural DNA,” said
Dr. Leproust.
“Today, we use phosphoramidite chemistry in our robust
commercial infrastructure to deliver billions of bases in DNA and
RNA products to serve almost 3,000 customers in fiscal 2021 alone.
We will continue to use this proven chemistry as we optimize our
enzymatic capabilities. We see enzymatic synthesis playing a
critical role in applications like DNA data storage, primers and
probes for PCR, cell-free production of plasmid DNA, qPCR assays,
decentralized DNA synthesis, and look forward to expanding our
markets by offering these applications either directly through our
channel or as OEM to our customers in the future,” she
continued.
Partnerships with PacBio and Singular Genomics
Twist also announced that it is enabling next-generation
sequencing (NGS) workflows for PacBio and Singular Genomics. Twist
has customized its robust target enrichment and library preparation
workflows for both sequencing platforms to allow customers to
experience the uniformity of the Twist Bioscience solution.
“Partnering with leading next-generation sequencing companies
that are driving the industry forward aligns with our strategy to
own the competitive landscape between the sample and the
sequencer,” continued Dr. Leproust. “Our unparalleled uniformity
encourages customers to sequence more for the same cost, ultimately
benefitting patients and the research community with richer
data.”
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Annual Report Form 10-K filed with the Securities and Exchange
Commission on November 23, 2021 and subsequent filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220110005295/en/
Angela Bitting SVP, Corporate Affairs 925-202-6211
abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024